circulating endoglin concentration is not elevated in chronic kidney disease循环endoglin浓度不高在慢性肾脏疾病.pdfVIP

Circulating Endoglin Concentration Is Not Elevated in Chronic Kidney Disease 1 1 2 1 2 David M. Charytan *, Alexander M. Helfand , Brian A. MacDonald , Angeles Cinelli , Raghu Kalluri , Elisabeth M. Zeisberg2 1 Renal Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 2 Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America Abstract Background: Soluble endoglin, a TGF-b receptor, plays a key role in cardiovascular physiology. Whether circulating concentrations of soluble endoglin are elevated in CKD or underlie the high risk of cardiovascular death associated with chronic kidney disease (CKD) is unknown. Methods: Individuals with and without CKD were recruited at a single center. Estimated glomerular filtration rate (eGFR) was estimated using the modified MDRD study equation and the serum creatinine at the time of recruitment, and patients were assigned to specific CKD stage according to usual guidelines. Serum endoglin concentration was measured by ELISA and univariate and multivariable regression was used to analyze the association between eGFR or CKD stage and the concentration of soluble endoglin. Results: Serum endoglin was measured in 216 patients including 118 with stage 3 or higher CKD and 9 individuals with end stage renal disease (ESRD). Serum endoglin concentration did not vary significantly with CKD stage (increase of 0.16 ng/mL per 1 stage increase in CKD, P = 0.09) or eGFR (decrease -0.06 ng/mL per 10 mL/min/1.73 m2 increase in GFR, P = 0.12), and was not higher in individuals with ESRD